SEC Filing Details

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

SEC Filing Details

Document Details

Form
Filing Date
Aug 10, 2022
Document Date
Aug 8, 2022
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Poseida Therapeutics, Inc.
Issuer
Poseida Therapeutics, Inc.
Filer
Malin Life Sciences Holdings Ltd